Literature DB >> 10925908

Endometrial adenocarcinoma--presenting pathology is a poor guide to surgical management.

R W Petersen1, J A Quinlivan, G R Casper, J L Nicklin.   

Abstract

We aimed to evaluate the correlation between the histological grade of endometrial cancer diagnosed on endometrial biopsy or curettage, with the definitive grade and stage of lesion as determined by surgery and histopathological examination and to make recommendations about the suitability of conservative surgery based on pre-operative determination of the grade of endometrial adenocarcinoma. A retrospective review of all patients with endometrial adenocarcinoma presenting to the Queensland Centre for Gynaecological Cancer from 1 January 1996 to 31 December 1998 was undertaken. Clinical and pathological data was abstracted from medical records and case notes of 460 patients. All histological specimens were prospectively reviewed by a panel consisting of gynaecologic pathologists, gynaecologic oncologists and other doctors involved in the treatment of patients with gynaecological malignancies. The percentage of patients whose management would have been optimised by full surgical staging at the time of initial surgery was calculated. Only 60%, 71%, and 84 % of the patients with a presenting diagnosis of grade 1, 2 and 3 endometrial adenocarcinomas respectively had this confirmed on final histopathology. Furthermore, using established criteria, 30%, 46% and 100% of patients presenting with grade 1, 2 and 3 endometrial adenocarcinoma required full surgical staging at the time of their primary surgery There is poor correlation between the pre-operative grade of endometrial cancer and the grade as determined on analysis of the resected uterus. The correlation is poorest with grade 1 endometrial adenocarcinoma, where strongest consideration is given to conservative surgery and the avoidance of subspecialty referral. There is a strong argument that all patients with a diagnosis of endometrial cancer made on endometrial biopsy or curettage, regardless of grade of malignancy, should be offered surgery where the option to perform concurrent comprehensive surgical staging is available.

Entities:  

Mesh:

Year:  2000        PMID: 10925908     DOI: 10.1111/j.1479-828x.2000.tb01145.x

Source DB:  PubMed          Journal:  Aust N Z J Obstet Gynaecol        ISSN: 0004-8666            Impact factor:   2.100


  4 in total

1.  Small non-coding RNA deregulation in endometrial carcinogenesis.

Authors:  Maria Ravo; Angela Cordella; Antonio Rinaldi; Giuseppina Bruno; Elena Alexandrova; Pasquale Saggese; Giovanni Nassa; Giorgio Giurato; Roberta Tarallo; Giovanna Marchese; Francesca Rizzo; Claudia Stellato; Rossella Biancardi; Jacopo Troisi; Attilio Di Spiezio Sardo; Fulvio Zullo; Alessandro Weisz; Maurizio Guida
Journal:  Oncotarget       Date:  2015-03-10

2.  PIpelle Prospective ENDOmetrial carcinoma (PIPENDO) study, pre-operative recognition of high risk endometrial carcinoma: a multicentre prospective cohort study.

Authors:  Nicole C M Visser; Johan Bulten; Anneke A M van der Wurff; Erik A Boss; Carolien M Bronkhorst; Harrie W H Feijen; Joke E Haartsen; Hilde A D M van Herk; Ineke M de Kievit; Paul J J M Klinkhamer; Brenda M Pijlman; Marc P M L Snijders; Ingrid Vandenput; M Caroline Vos; Peter E J de Wit; Lonneke V van de Poll-Franse; Leon F A G Massuger; Johanna M A Pijnenborg
Journal:  BMC Cancer       Date:  2015-06-30       Impact factor: 4.430

3.  Tissue microarray is suitable for scientific biomarkers studies in endometrial cancer.

Authors:  Nicole C M Visser; Anneke A M van der Wurff; Johanna M A Pijnenborg; Leon F A G Massuger; Johan Bulten; Iris D Nagtegaal
Journal:  Virchows Arch       Date:  2018-02-09       Impact factor: 4.064

4.  Assessment of endometrial sampling as a predictor of final surgical pathology in endometrial cancer.

Authors:  L Helpman; R Kupets; A Covens; R S Saad; M A Khalifa; N Ismiil; Z Ghorab; V Dubé; S Nofech-Mozes
Journal:  Br J Cancer       Date:  2013-12-24       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.